Heqirui Pharmaceutical is a science-driven clinical-stage innovative biopharmaceutical company with R&D bases and offices in Beijing, Shanghai and Nanjing. The company was founded on translational research led by Professor Xiao Ruiping and his team at Peking University's Future Technology Institute. Heqirui focuses on women's health, endocrine and cardiovascular disease areas and is building a diversified pipeline to address unmet clinical needs. Its development model combines in-house R&D with patent in-licensing. The core pipeline includes HMI-115, a monoclonal antibody currently conducting two international Phase II clinical studies. The company recently completed a nearly RMB 200 million B+ financing to support HMI-115's international trials and continued development of other product lines. Hope Medicine Inc. (HopeMed) is a global, science-driven innovative biopharmaceutical company founded by Professor Rui‑Ping Xiao with R&D bases and offices in Nanjing, Shanghai, and Beijing. The company focuses on first-in-class drugs in women's health, endocrinology, and cardiovascular areas through independent R&D and license‑in models. Its pipeline includes HMI‑115, a prolactin receptor antibody in-licensed from Bayer for androgenic alopecia and endometriosis; HMI‑115 completed Phase I trials in the EU with positive safety results. HopeMed plans to launch global multi-center Phase II (MRCT) trials for androgenic alopecia and endometriosis and to advance commercial product development. The company emphasizes building an international multidisciplinary team and strengthening global intellectual property to address unmet medical needs. HopeMed completed a significant Series B financing to support its upcoming international clinical studies and further development of its pipeline.

Total raised

$84M

Funding rounds

2

Latest round

Series B

Latest activity

Feb 2024